81 related articles for article (PubMed ID: 8067185)
1. [Plasma serine protease inhibitors in patients with liver cirrhosis].
Piatkowska M; Kotschy M; Rość D; Wiśniewska E; Opoka J
Acta Haematol Pol; 1994; 25(2):145-9. PubMed ID: 8067185
[TBL] [Abstract][Full Text] [Related]
2. [Serine protease inhibitors in plasma of patients with ulcerative colitis].
Swiatkowski M; Pulkowski G; Kłopocka M; Budzyński J; Wiśniewsk E; Kotschy M
Przegl Lek; 2001; 58(2):67-70. PubMed ID: 11475845
[TBL] [Abstract][Full Text] [Related]
3. [Plasma serine protease inhibitors in dialyzed patients with chronic renal insufficiency].
Kotschy M; Kassian J; Lampka M; Rajewski W
Pol Merkur Lekarski; 1997 Feb; 2(8):93-5. PubMed ID: 9538647
[TBL] [Abstract][Full Text] [Related]
4. [Protein C and plasma serine protease inhibitors in patients with essential hypertension].
Kłoczko J; Bielawiec M; Galar M; Czaczkowska T; Wojtukiewicz M
Pol Tyg Lek; 1991 Dec 26-30; 46(50-52):974-6. PubMed ID: 1669185
[TBL] [Abstract][Full Text] [Related]
5. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
6. Natural protease inhibitors to fibrinolysis in liver diseases.
Arnman R; Gyzander E; Hedner U; Olsson R; Teger-Nilsson AC
Hepatogastroenterology; 1980 Aug; 27(4):254-8. PubMed ID: 6162766
[TBL] [Abstract][Full Text] [Related]
7. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
8. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis.
Violi F; Ferro D; Basili S; Quintarelli C; Musca A; Cordova C; Balsano F
Hepatology; 1993 Jan; 17(1):78-83. PubMed ID: 8423044
[TBL] [Abstract][Full Text] [Related]
9. [Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia].
Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):75-6. PubMed ID: 8756735
[TBL] [Abstract][Full Text] [Related]
10. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?
Ben-Ari Z; Osman E; Hutton RA; Burroughs AK
Am J Gastroenterol; 1999 Oct; 94(10):2977-82. PubMed ID: 10520855
[TBL] [Abstract][Full Text] [Related]
11. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma.
Marlar RA; Kressin DC; Madden RM
Thromb Haemost; 1993 Jan; 69(1):16-20. PubMed ID: 8383358
[TBL] [Abstract][Full Text] [Related]
12. Circadian rhythms of fibrinogen and antithrombin III in liver cirrhosis.
Pasqualetti P; Casale R
Riv Eur Sci Med Farmacol; 1995; 17(4):125-9. PubMed ID: 8545565
[TBL] [Abstract][Full Text] [Related]
13. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis].
Matsuura R; Soma M; Maeda Y; Kasakura S
Rinsho Byori; 1995 Dec; 43(12):1256-60. PubMed ID: 8569037
[TBL] [Abstract][Full Text] [Related]
14. [The plasma levels of urokinase plasminogen activator and plasminogen activator inhibitor-1 and the protein expressions of alpha-SMA and MMP-1 and TIMP-1 in patients with different grades of liver fibrosis].
Bai K; Guo CJ
Zhonghua Gan Zang Bing Za Zhi; 2006 Jun; 14(6):459-61. PubMed ID: 16792874
[No Abstract] [Full Text] [Related]
15. Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Song KS; Lee A; Choi JR; Kwon OH
Thromb Haemost; 1995 Sep; 74(3):864-7. PubMed ID: 8571313
[TBL] [Abstract][Full Text] [Related]
16. [The plasma levels of transforming growth factor beta1 and the protein expressions of alpha-SMA, urokinase plasminogen activator and plasminogen activator inhibitor-1 in liver of patients with different grades of hepatic fibrosis].
Wu XR; Lv MH; Wang Q; Shi SS; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):400-2. PubMed ID: 15268802
[TBL] [Abstract][Full Text] [Related]
17. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin.
Llamas P; Cabrera R; Gómez-Arnau J; Fernández MN
Haematologica; 1998 Apr; 83(4):338-46. PubMed ID: 9592984
[TBL] [Abstract][Full Text] [Related]
18. [The relationship between hemostatic changes in liver cirrhosis patients with different degrees of liver lesions in reference to Child-Pugh scores].
Cong YL; Wei YX; Zhang LW; Yin ZJ; Bai J
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):31-4. PubMed ID: 15670488
[TBL] [Abstract][Full Text] [Related]
19. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh scores.
Kiki I; Yilmaz O; Erdem F; Gundogdu M; Demircan B; Bilici M
Int J Clin Pract; 2006 Sep; 60(9):1075-9. PubMed ID: 16939549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
